Syrian government air strikes overnight put four hospitals in Aleppo province out of action, the British-based Syrian Observatory for Human Rights said on Sunday. The strikes hit near the hospitals, it said.
France's Sanofi said on Sunday that two late-stage Phase III clinical trials of its LixiLan diabetes drug had met their targets, readying it for approval in the United States in August and Europe early next year. LixiLan consists of a single-injection combination of Lyxumia, a drug developed with Danish drugmaker Zealand Pharma, and Sanofi's Lantus. It targets patients suffering from type 2 diabetes.
BEIJING (Reuters) – U.S. Treasury Secretary Jack Lew said on Sunday he believes China and the United States can make progress in opening China’s financial and healthcare sectors.
Swiss drugmaker Novartis will invest up to an extra $15 million in Gamida Cell, an Israeli developer of stem cell therapies, Gamida said on Sunday. Novartis last year invested $35 million in the company for a 15 percent stake, in a deal that could reach $600 million if Novartis exercises a buyout option that expires in 2016. The $15 million investment will be used to advance Gamida Cell's clinical programs, including the development of NiCord, an experimental treatment for patients with high risk hematological malignancies, or blood cancers such as leukemia and lymphoma and sickle cell disease.
LONDON, July 12 (Reuters) – England have named an unchanged 13-man squad for the second Ashes test at Lord’s next week having thrashed Australia by 169 runs in Cardiff on Saturday to take a 1-0 series lead, the England and Wales Cricket Board (ECB) said on Sunday. England won the opening test inside four days having bowled Australia out for 242, who were chasing a daunting 412 to win, and banished memories of the humiliating 5-0 Ashes whitewash in the previous series down under. …